Tardieve Dyskinesie

Klinisch beeld1,2
Hoe vaak komt het voor? Wie zijn kwetsbaar?1,3-6
Beloop1,7-10
Wat kan het anders zijn?2,11
Bijzonderheden12,13
Behandeling14-24

  1. Stegmayer K, Walther S, van Harten P. Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies. CNS Drugs 2018; 32(2): 135-47.
  2. Sienaert P, van Harten P, Rhebergen D. The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia. Handb Clin Neurol 2019; 165: 415-28.
  3. Bakker PR, de Groot IW, van Os J, van Harten PN. Predicting the incidence of antipsychotic-induced movement disorders in long-stay patients: A prospective study. Epidemiology and psychiatric sciences 2013; 22(4): 375-9.
  4. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. The American journal of psychiatry 2006; 163(8): 1438-40.
  5. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World psychiatry : official journal of the World Psychiatric Association 2018; 17(3): 330-40.
  6. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2020; 34(1): 3-78.
  7. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry 2008; 69(10): 1580-8.
  8. Eberhard J, Lindstrom E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006; 21(1): 35-42.
  9. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, Group SS. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005; 66(9): 1130-3.
  10. Tenback DE, van Harten PN, Slooff CJ, van Os J, Group SS. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry 2007; 48(5): 436-40.
  11. Tenback D, Van Harten PN. Epidemiology and Risk Factors for (Tardive) Dyskinesia. In: Brotchie J, Bezard E, Jenner P, eds. Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia. NY: Elsevier; 2011.
  12. van Harten PN, Bakker PR, Mentzel CL, Tijssen MA, Tenback DE. Movement disorders and psychosis, a complex marriage. Frontiers in psychiatry 2014; 5: 190.
  13. Borsboom D. A network theory of mental disorders. World psychiatry : official journal of the World Psychiatric Association 2017; 16(1): 5-13.
  14. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018; 12: 1215-38.
  15. Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: A meta-analysis. J Clin Psychiatry 2018; 79.
  16. Patel RS, Mansuri Z, Motiwala F, et al. A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. Ther Adv Psychopharmacol 2019; 9: 2045125319847882.
  17. Krause P, Kroneberg D, Gruber D, Koch K, Schneider GH, Kuhn AA. Long-term effects of pallidal deep brain stimulation in tardive dystonia: a follow-up of 5-14 years. J Neurol 2022; 269(7): 3563-8.
  18. Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry 2012; 73(11): 1434-8.
  19. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011; (2): CD000209.
  20. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry 2019; 64(6): 388-99.
  21. Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(2): 507-9.
  22. Soares KV, McGrath JJ. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000; (2): CD000206.
  23. Wong J, Pang T, Cheuk NKW, Liao Y, Bastiampillai T, Chan SKW. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders. Psychopharmacology (Berl) 2022; 239(11): 3393-420.
  24. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World psychiatry : official journal of the World Psychiatric Association 2018; 17(3): 341-56.
Copyright © 2024 Prof. dr. P.N. van Harten. Alle rechten voorbehouden.